Marta Ruiz-Ortega sheds light on the new and exciting field of epigenetics, and how BET inhibition might provide an interesting therapeutic target in renal disease. She shares experimental data dat demonstrate the beneficial effects of BET inhibition.
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
Marta Ruiz-Ortega, PhD , Fundación Jiménez Díaz,Madrid, Spain
The symposium was supported by an unrestricted educational grant from Resverlogix CorpThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?
Kamyar Kalantar-Zade, MD
- Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?
Luis M Ruilope, MD